Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer’s Disease

This open-label pilot evaluates psilocybin administered in two sessions alongside weekly psychological support in up to 20 participants with Mild Cognitive Impairment or early Alzheimer’s disease and clinically significant depressive symptoms.

Dosing: first session 15 mg/70 kg (week 4); second session 15 or 25 mg/70 kg (week 6) per study team discretion. Primary outcome is change in depressed mood one week after the second session versus pre-treatment; follow-up extends to six months.